U臒ur 脰zkerim路 @UOzkerim 路 X路路 14 hours agoScore70
Body
馃毃 Impressive results from #ESMO2026!
Phase III DeLLphi-305: Tarlatamab + durvalumab vs durvalumab alone as 1L maintenance in ES-SCLC:
馃敼 Median OS: 21.1 vs 12.7 months (HR 0.42)
馃敼 Median PFS: 7.4 vs 1.9 months (HR 0.34)
馃敼 ORR: 26.4% vs 4.1%
馃敟 Practice-changing potential!
#LungCancer #SCLC
@OncoAlert @weoncologists @StephenVLiu @GlopesMd @ManuelDomine
92 views 路 4 likes 路 3 reposts 路 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: U臒ur 脰zkerim 路 x.com